AstraZeneca PLC AZN
184.45 USD +0.07 (+0.04%)
Regular-session close
185.06 +0.61 +0.33%
After hours · Nov 13, 7:54 PM ET
183.94 Day range 186.15
155.62 52-week range 209.48
- YTD
- +0.32%
- 1 year
- +4.08%
News
businesswire.com Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant…
benzinga.com FDA Approves Durvalumab With Enfortumab Vedotin-Ejfv For Muscle-Invasive Bladder Cancer https://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer
reuters.com AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
benzinga.com 'AstraZeneca Cuts 600 US Sales Staff as Savings Drive Kicks In'- Bloomberg https://www.bloomberg.com/news/articles/2026-11-13/astrazeneca-cuts-600-us-sales-staff-as-savings-drive-kicks-in
reuters.com EU panel backs AstraZeneca hypertension drug baxdrostat EU panel backs AstraZeneca hypertension drug baxdrostat
defenseworld.net AlphaCore Capital LLC Buys 3,357 Shares of AstraZeneca Plc $AZN AlphaCore Capital LLC increased its stake in AstraZeneca Plc (NYSE: AZN) by 78.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,656…
seekingalpha.com AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline AstraZeneca's specialty medicines in Oncology, Respiratory, and Rare Diseases are driving double-digit growth, offsetting patent cliff impacts in legacy drugs. AZN trades at a significant valuation…
businesswire.com AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity…
benzinga.com AstraZeneca Acquires Omniose; Financial Terms Not Disclosed Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with…
businesswire.com Omniose Announces Its Acquisition by AstraZeneca ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research…
defenseworld.net 7,250 Shares of AstraZeneca Plc $AZN Purchased by CenterBook Partners LP CenterBook Partners LP acquired a new stake in AstraZeneca Plc (NYSE: AZN) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm…
defenseworld.net AstraZeneca Plc $AZN Stock: Ethic Inc. Grows Holdings Ethic Inc. raised its holdings in AstraZeneca Plc (NYSE: AZN) by 27.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional…
defenseworld.net AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages AstraZeneca Plc (NYSE: AZN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Three…
wsj.com AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
benzinga.com Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.
benzinga.com AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing AstraZeneca posts strong Q3; RBC raises target, citing reduced AVANZAR uncertainty and promising pipeline catalysts.
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.
defenseworld.net 27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC International Assets Investment Management LLC boosted its stake in AstraZeneca Plc (NYSE: AZN) by 1,564.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned…
defenseworld.net 1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich bought a new stake in AstraZeneca Plc (NYSE: AZN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…
fool.com AstraZeneca: 3 Key Takeaways for Long-Term Investors Total revenue grew 7% across the first nine months of 2026. AstraZeneca launched a $2 billion restructuring initiative through 2029.
defenseworld.net AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell? AstraZeneca Plc (NYSE: AZN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $180.21 and traded as high as…
defenseworld.net AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC Brian Low Financial Group LLC increased its position in shares of AstraZeneca Plc (NYSE: AZN) by 32.6% during the third quarter, according to the company in its most recent disclosure with the…
defenseworld.net AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell? AstraZeneca PLC (LON: AZN - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02.…
seekingalpha.com AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
marketbeat.com AstraZeneca Q3 Earnings Call Highlights AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology,…
benzinga.com AstraZeneca Q3 2026 Earnings Call Transcript AstraZeneca (NASDAQ:AZN) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
benzinga.com AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth AstraZeneca beats Q3 2026 targets as oncology offsets Farxiga losses, backed by a $2 billion pipeline restructuring push.
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus (UPDATED) U.S. stock were mixed on Friday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different direction.- benzinga.com AstraZeneca Shares Rise After Q3 Earnings Beat, Reaffirmed 2026 Outlook AstraZeneca Plc (NASDAQ:AZN) shares are trading higher Friday after the drugmaker reported third-quarter results that topped analyst estimates and reaffirmed its full-year guidance.What To Know:…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds plunge to 14% as Wall Street reacts to Alphabet's 10% drop, rising oil, and a broad tech selloff.
benzinga.com ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…- benzinga.com Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…
benzinga.com Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.
benzinga.com AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgeryData demonstrated statistically significant and…
benzinga.com AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trialResults reinforce IMFINZI as the…
benzinga.com FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug FDA grants accelerated approval to AstraZeneca's Ultomiris for adult IgAN to lower proteinuria, pending data on long-term kidney benefit.
benzinga.com AstraZeneca Launches ZEGFROVY In The U.S., Expanding Targeted Treatment Options For EGFR Exon 20 Insertion-Mutated Lung Cancer Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapyLaunch expands AstraZeneca’s commitment to addressing substantial unmet need across the…
benzinga.com Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks Late-breaking results from I CAN Phase…
benzinga.com AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
benzinga.com 'A Surprisingly Large Amount Of Your Investment Is Divided Across Just 7 Companies' — Former Investment Banker Says She's Changing How She Invests The S&P 500 has long been a favorite among investors looking to build wealth, with historical annual returns averaging around 10%. But former investment banker Nischa Shah says she’s changing how she…- benzinga.com Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and…
benzinga.com AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs.…
benzinga.com Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.- benzinga.com Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.- benzinga.com AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026 CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patientsSAFFRON results will highlight clinical…
benzinga.com AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
benzinga.com AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.